Search results for " PC"

showing 10 items of 434 documents

Changes in estimating echocardiography pulmonary capillary wedge pressure after hypersaline plus furosemide versus furosemide alone in decompensated …

2011

BACKGROUND: The aim of the study was to verify the effects of hypertonic saline solution (HSS) plus a high furosemide dose and light restriction of sodium intake compared with a high-dose infusion of furosemide alone on pulmonary capillary wedge pressure (PCWP), as determined by Doppler echocardiography and tissue Doppler imaging in patients suffering from decompensated heart failure. METHODS AND RESULTS: Consecutive patients in New York Heart Association functional class IV, unresponsive to oral high doses of furosemide up to 250-500 mg/d and/or combinations of diuretics, with ejection fraction <40%, serum creatinine <2 mg/dL, blood urea nitrogen ≤60 mg/dL, reduced urinary volume (<500 mL/…

MaleSettore MED/09 - Medicina Internamedicine.medical_treatmentHemodynamicsDoppler echocardiographyDouble-Blind MethodFurosemidemedicinePlethysmographHumansPlethysmography ImpedancePulmonary Wedge PressurePulmonary wedge pressureDiureticsAgedAged 80 and overHeart FailureSaline Solution HypertonicEjection fractionmedicine.diagnostic_testDiuretics Saline Solution Hypertonic Furosemide PCWPbusiness.industryFurosemidemedicine.diseaseEchocardiographyHeart failureAnesthesiaFemaleDiureticCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Long-term follow-up after drug eluting stent implantation in left main trifurcations

2009

Aims: Trifurcation lesions, which are mostly observed in distal left main (LM), represent a technical challenge for interventional cardiologists. We sought to determine the feasibility and long-term clinical outcome of drug eluting stent (DES) implantation in patients with LM coronary trifurcation lesions. Methods and results: All patients with clinically significant de novo LM trifurcation lesions, who refused coronary artery bypass surgery and were considered eligible for percutaneous coronary intervention (PCI), were consecutively enrolled in this study from November 2005 to February 2007. Eleven patients (65±9 years, 91% men) met all the inclusion criteria and underwent LM trifurcation …

MaleTarget lesionmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentTrifurcation lesions.Coronary DiseaseCoronary AngiographyCoronary artery bypass surgeryClinical endpointStentHumansMedicineMyocardial infarctionAgedSirolimusbusiness.industryAngioplastyStentPercutaneous coronary interventionDrug-Eluting StentsEquipment DesignMiddle Agedmedicine.diseaseCoronary VesselsDESTubulin ModulatorsSurgeryDrug-eluting stentConventional PCIFemaleRadiologyCardiology and Cardiovascular MedicinebusinessImmunosuppressive AgentsFollow-Up Studies
researchProduct

Retrograde Recanalization of Chronic Total Occlusions in Europe: Procedural, In-Hospital, and Long-Term Outcomes From the Multicenter ERCTO Registry.

2015

BACKGROUND A retrograde approach improves the success rate of percutaneous coronary interventions (PCIs) for chronic total occlusions (CTOs). OBJECTIVES The authors describe the European experience with and outcomes of retrograde PCI revascularization for coronary CTOs. METHODS Follow-up data were collected from 1,395 patients with 1,582 CTO lesions enrolled between January 2008 and December 2012 for retrograde CTO PCI at 44 European centers. Major adverse cardiac and cerebrovascular events were defined as the composite of cardiac death, myocardial infarction, stroke, and further revascularization. RESULTS The mean patient age was 62.0 +/- 10.4 years; 88.5% were men. Procedural and clinical…

MaleTime FactorsIncidenceMiddle AgedCoronary AngiographySettore MED/11 - Malattie Dell'Apparato CardiovascolareHospitalsEuropeElectrocardiographyPercutaneous Coronary InterventionPostoperative ComplicationsTreatment OutcomeCoronary Occlusionchronic total occlusionsJ-CTO scoreChronic DiseaseHumansretrograde PCI revascularizationFemaleHospital MortalityProspective StudiesRegistrieschronic total occlusionFollow-Up StudiesJournal of the American College of Cardiology
researchProduct

Survival benefit from recent changes in management of men and women with ST-segment elevation myocardial infarction treated with percutaneous coronar…

2019

Background: Nowadays, the majority of patients with myocardial infarction with ST-segment elevation (STEMI) are treated with primary percutaneous coronary interventions (PCI). In recent years, there have been ongoing improvements in PCI techniques, devices and concomitant pharmacotherapy. However, reports on further mortality reduction among PCI-treated STEMI patients remain inconclusive. The aim of this study was to compare changes in management and mortality in PCI-treated STEMI patients between 2005 and 2011 in a real-life setting. Methods: Data on 79,522 PCI-treated patients with STEMI from Polish Registry of Acute Coronary Syndromes (PL-ACS) admitted to Polish hospitals between 2005 an…

MaleTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicinetemporal trendsRisk Factorstreatment strategyST segmentMyocardial infarctionHospital MortalityRegistriesPractice Patterns Physicians'Mortality rateGeneral MedicineMiddle AgedInterventional Cardiologysurgical procedures operativeTreatment OutcomePractice Guidelines as TopicCardiologyFemaleStentsGuideline AdherenceCardiology and Cardiovascular Medicinemedicine.medical_specialtyRisk Assessment03 medical and health sciencesPharmacotherapyPercutaneous Coronary InterventionSex FactorsInternal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeHealthcare DisparitiesAgedRetrospective Studiesbusiness.industryPercutaneous coronary interventionCardiovascular AgentsHealth Status Disparitiesmedicine.diseaseST-segment elevation myocardial infarctionConcomitantPropensity score matchingConventional PCI1-year mortalityST Elevation Myocardial InfarctionPolandbusinesssex-differencesin-hospital mortality
researchProduct

How to preserve and handle fish liver samples to conserve RNA integrity

2019

As transcriptomic studies are becoming more and more common, it is important to ensure that the RNA used in the analyses is of good quality. The RNA integrity may be compromised by storage temperature or freeze-thaw cycles, but these have not been well studied in poikilothermic fishes. This work studied the effects of tissue storage time and temperature, and freeze-thaw cycles of tissue and extracted RNA on RNA integrity in brown trout (Salmo trutta L.) liver. The storage time and temperature had an effect on RNA integrity, but RNA suitable for quantitative reverse transcription PCR (RT-qPCR) (RIN > 7) was still obtained from samples preserved at − 20 °C for 6 months. Freeze-thaw cycles of …

MaleTroutBleached kraft pulp mill effluentHealth Toxicology and Mutagenesis010501 environmental sciencesSample storage01 natural sciencessäilytysSpecimen HandlingTranscriptomeBrown troutsample storageFish liverFreezingAnimalsEnvironmental Chemistryteollisuusjätevesi14. Life underwaterSalmoGene0105 earth and related environmental scienceskalatCryopreservationQuantitative reverse transcription PCRbiologyReverse Transcriptase Polymerase Chain ReactionsytokromitmaksaRNAnäytteetGeneral MedicineRna degradationbiology.organism_classificationPollutionbleached kraft pulp mill effluentPoikilothermLiverBiochemistrycytochrome p450quantitative reverse transcription PCRRNACytochrome p450TranscriptomeResearch ArticleRNA integrity
researchProduct

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention …

2019

Background: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI. Methods: Using a 2×2 factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y 12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: patients with ACS treated medically, patients with ACS treated with PCI,…

MaleVitamin Kmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicineAntithromboticAtrial Fibrillation//purl.org/pe-repo/ocde/ford#3.02.04 [https]030212 general & internal medicineProspective Studies610 Medicine &amp; healthAspirinVKADisease ManagementAtrial fibrillationVitamin K antagonistMiddle AgedCombined Modality TherapyHospitalizationTreatment Outcomesurgical procedures operativeElective Surgical ProceduresCardiologyApixabanDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyAcute coronary syndromemedicine.drug_classPyridonesDOACHemorrhageP2Y12 inhibitor03 medical and health sciencesPercutaneous Coronary InterventionFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeAgedProportional Hazards ModelsAspirinbusiness.industryPercutaneous coronary interventionAnticoagulantsCardiovascular Agentsmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsPyrazolesbusinessPlatelet Aggregation Inhibitors
researchProduct

Comparative multiplex dosage analysis in spinocerebellar ataxia type 2 patients.

2013

We developed a new application of comparative multiplex dosage analysis (CMDA) for evaluation of the ataxin 2 gene. Expansions of the triplet CAG can cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disease with an autosomal-dominant mode of inheritance. Molecular diagnosis of SCA2 is routinely based on the use of conventional PCR to detect the CAG expansion. However, PCR does not amplify an allele with an expansion of many triplets (>80), which is typically found in infantile and juvenile forms of SCA2, thus leading to false negatives. We propose the analysis of the ATXN2 gene by CMDA to complement existing methods currently used for the detection of large expansions of the …

Malecongenital hereditary and neonatal diseases and abnormalitiesGenotypeGene DosagePrenatal diagnosisNerve Tissue ProteinsDiseaseAtaxin 2 Spinocerebellar ataxia type 2 Quantitative PCR Autosomal dominant Prenatal diagnosisSettore BIO/13 - Biologia ApplicataGeneticsMedicineHumansSpinocerebellar AtaxiasMultiplexAlleleMolecular BiologyGeneAllelesGeneticsbusiness.industryGeneral Medicinemedicine.diseaseReal-time polymerase chain reactionAtaxinsAtaxinCase-Control StudiesSpinocerebellar ataxiaFemalebusinessTrinucleotide Repeat ExpansionMultiplex Polymerase Chain ReactionGenetics and molecular research : GMR
researchProduct

Argatroban for elective percutaneous coronary intervention: The ARG-E04 multi-center study

2011

The synthetic arginine-derived direct thrombin inhibitor argatroban is an attractive anticoagulant for percutaneous coronary intervention (PCI), because of its rapid onset and offset, and its hepatic elimination. Argatroban was approved for PCI in patients with heparin-induced thrombocytopenia (HIT). However, there are limited data about argatroban in non-HIT patients. The objective of this open-label, multiple-dose, controlled study was to examine the safety and efficacy of argatroban in patients undergoing elective PCI.Of 140 patients randomized to three argatroban dose groups (ARG250, ARG300, and ARG350 with 250, 300, or 350 μg/kg bolus, followed by 15, 20, or 25 μg/kg/min infusion) and …

Malemedicine.drug_classmedicine.medical_treatmentActivated clotting timeHemorrhageArginineAntithrombinsArgatrobanBolus (medicine)medicineHumansAngina UnstableMyocardial infarctionAngioplasty Balloon CoronaryBlood CoagulationAgedSulfonamidesDose-Response Relationship Drugmedicine.diagnostic_testHeparinbusiness.industryAnticoagulantAnticoagulantsPercutaneous coronary interventionThrombosisMiddle Agedmedicine.diseaseDirect thrombin inhibitorPipecolic AcidsAnesthesiaConventional PCIFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugInternational Journal of Cardiology
researchProduct

Timing of percutaneous coronary intervention in troponin-negative patients with acute coronary syndrome without persistent ST-segment elevation: prel…

2015

OBJECTIVE Management of acute coronary syndromes without persistent ST-segment elevation (NSTE-ACS) and unstable angina pectoris (UAP) remains challenging. The study aimed to analyze the current management of UAP patients in German chest pain units focussing on the different time lines of invasive strategy. METHODS A total of 1400 UAP patients admitted to a certified chest pain unit were enrolled. Analyses of high-risk criteria with indication for invasive management and of 3-month clinical outcomes were performed by subgrouping UAP patients to immediate and early invasive (<8 hours), early elective invasive (8-24 hours), late elective invasive (24-72 hours) strategy, and without percutaneo…

Malemedicine.medical_specialtyAcute coronary syndromeChest PainTime Factorsmedicine.medical_treatmentOperative TimeChest painCoronary AngiographyElectrocardiographyPatient AdmissionPercutaneous Coronary InterventionInternal medicineGermanyMedicineST segmentHumansRegistriesAcute Coronary SyndromeAgedRetrospective Studiesbusiness.industryUnstable anginaCoronary Care UnitsPercutaneous coronary interventionRetrospective cohort studyMiddle Agedmedicine.diseaseTroponinRegimenTreatment OutcomeConventional PCICardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesCritical pathways in cardiology
researchProduct

Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes

2013

Item does not contain fulltext BACKGROUND: Although P2Y12 antagonists are effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes, the effect of the timing of administration--before or after coronary angiography--is not known. We evaluated the effect of administering the P2Y12 antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography if percutaneous coronary intervention (PCI) was indicated. METHODS: We enrolled 4033 patients with NSTE acute coronary syndromes and a positive troponin level who were scheduled to undergo coronary angiography within 2 to 48 hours after randomization. Patients were randomly assigned to recei…

Malemedicine.medical_specialtyAcute coronary syndromePrasugrelmedicine.medical_treatmentPremedicationMyocardial InfarctionHemorrhageThiophenesCoronary AngiographyPiperazinesPercutaneous Coronary InterventionDouble-Blind MethodInternal medicinemedicineHumansMyocardial infarctionAcute Coronary SyndromeCoronary Artery BypassAgedCardiovascular diseases [NCEBP 14]business.industryMedicine (all)Hazard ratioAcute Coronary Syndrome; Aged; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Coronary Angiography; Premedication; Medicine (all)Percutaneous coronary interventionGeneral MedicineThrombolysisMiddle Agedta3121medicine.diseaseConventional PCICardiologyPurinergic P2Y Receptor AntagonistsFemalebusinessPrasugrel HydrochlorideTIMImedicine.drug
researchProduct